Immunoadsorption
Immunoadsorption or IA is an the technique by which immunoglobulins, especially undesirable antibodies, are removed from blood plasma. Repeat Immunoadsorption or RIA involves a series of immunoadsorption treatments at fixed intervals.[1] Immonoadsorption is an apheresis treatment which has been investigated for ME/CFS and Long COVID patients.[2][1]
Theory[edit | edit source]
A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[2]
Evidence[edit | edit source]
A pilot study published before peer-review found Repeat Immunoadsorption was effective in improving ME/CFS symptoms in 10 patients with Long COVID who met the Canadian Consensus Criteria for ME/CFS, after developing ME/CFS after COVID-19 infection.[1]
Notable studies[edit | edit source]
- 2023, Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies[1] - (Preprint - Full text)
- 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[2] (Full Text)
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[3] Several medical conditions, such as multiple sclerosis[4] and chronic inflammatory demyelinating polyneuropathy (CIDP) may use immunoadsorption as part of their medical regimen.[5]
Costs and availability[edit | edit source]
Learn more[edit | edit source]
- Wikipedia
- 2018, Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward (Carmen Scheibenbogen)
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 1.2 1.3 Stein, Elisa; Heindrich, Cornelia; Wittke, Kirsten; Kedor, Claudia; Kim, Laura; Freitag, Helma; Krueger, Anne; Toelle, Markus; Scheibenbogen, Carmen (September 1, 2023). "Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies". medrxiv: 2023.08.31.23294813. doi:10.1101/2023.08.31.23294813.
- ↑ 2.0 2.1 2.2 Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald (March 15, 2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLOS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672. ISSN 1932-6203. PMC 5854315. PMID 29543914.
- ↑ Pham, H.P.; Schwartz, J. (2013). "79 - Immunoadsorption". In Shaz, B. H.; Hillyer, C.D. (eds.). Transfusion medicine and hemostasis: clinical and laboratory aspects (2 ed.). Newnes. pp. 525–527. doi:10.1016/B978-0-12-397164-7.00079-3.
- ↑ Koziolek, Michael J.; Tampe, Desiree; Bähr, Matthias; Dihazi, Hassan; Jung, Klaus; Fitzner, Dirk; Klingel, Reinhard; Müller, Gerhard A.; Kitze, Bernd (April 26, 2012). "Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis". Journal of Neuroinflammation. 9 (1): 80. doi:10.1186/1742-2094-9-80. ISSN 1742-2094. PMC 3418188. PMID 22537481.
- ↑ Lehmann, Helmar C.; Hughes, Richard A.C.; Hartung, Hans-Peter (January 1, 2013). "23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy". In Said, Gérard; Krarup, Christian (eds.). Handbook of Clinical Neurology. Peripheral Nerve Disorders. 3. 115. Elsevier. pp. 415–427. doi:10.1016/b978-0-444-52902-2.00023-0.
